SAN JOSE, Calif., Feb. 28, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data in an oral minisymposium presentation from its study utilizing Anixa's artificial intelligence (AI) driven early cancer detection technology.  The presentation will be made at the 2019 annual meeting of the American Association for Cancer Research (AACR) in Atlanta, Georgia.  The meeting will be held March 29–April 3, 2019 and will be attended by world leading experts across the field of cancer research.  All abstracts are currently available to view by registered attendees on the online itinerary planner. 

Oral Minisymposium Presentation:

Abstract Control Number: 598
Title:  Using machine learning to predict the risk of either having an aggressive form of prostate cancer (PCa) or lower grade PCa/benign prostatic hyperplasia (BPH) based upon the flow cytometry immunophenotyping of myeloid-derived suppressor cells (MDSCs) and lymphocyte cell populations
Presenter:  George A. Dominguez, PhD – Senior Clinical Research Scientist
Session Title:  Biomarkers for Early Detection and Biologic Assessment of Cancer
Session Start:  Sunday March 31, 2019 3:00 PM ET
Session End:  Sunday March 31, 2019 5:00 PM ET

The presentation will focus on the continuing research progress of Anixa's AI technology that combines the fields of flow cytometry with artificial intelligence featuring new data and insights into its application for early prostate cancer detection. 

"We are pleased to be giving an oral presentation at this AACR symposium focusing on early detection of cancer," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences.

American Association for Cancer Research (AACR)
The American Association for Cancer Research (AACR) (www.aacr.org) is a 501(c)(3) public charity headquartered in Philadelphia, PA.  The mission of the AACR is to prevent and cure cancer through research, education, communication and collaboration.  Through its programs and services, the AACR fosters cancer research and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer causes, prevention, diagnosis and treatment throughout the world.

About Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.  It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy.  It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at www.anixa.com.

Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-latest-prostate-cancer-data-at-the-2019-american-association-for-cancer-research-aacr-annual-meeting-300803835.html

SOURCE Anixa Biosciences, Inc.